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ABSTRACT
Pseudomonas aeruginosa is one of the most common bacterium with a broad spectrum 
of human-associated infections. It is intrinsically resistant to many antimicrobial drugs, 
making carbapenems crucial in clinical management. The emergence and dissemination of 
carbapenemases among P. aeruginosa clinical isolates is a serious public health concern as it 
limits the options for the treatment of bacterial infections. Here, we described the molecular 
and epidemiological characteristics of 28 carbapenem-resistant P. aeruginosa strains isolated 
from patients hospitalized in an intensive care unit (ICU). The antimicrobial susceptibility 
of carbapenem-resistant P. aeruginosa strains was determined by broth microdilution. The 
presence of resistance genes was evaluated by PCR and DNA sequencing. Additionally, 
alterations in genes encoding P. aeruginosa outer membrane proteins were analyzed by PCR 
as well as SDS-PAGE. Clinical characteristics of the patients and the economic impact of 





 genes were identified in three isolates (11%) and bla
SHV
 gene in two 
isolates (7%). Outer membrane profiles obtained by SDS–PAGE indicated that the OprD 
porin was either absent or was produced at very low levels. A PCR assay using oprD-specific 
primers failed to show the presence of mutations in this gene. P. aeruginosa strains were 
isolated from 28 patients, among whom 43% (12/28) had sepsis, 31% (9/28) had respiratory 
failure, and 31% (9/28) had systemic arterial hypertension. A high mortality rate (39%) 
was observed in these patients, with an average duration of hospitalization of 34.6 days 
and a median cost of 3.275 dollars per patient. The production of carbapenemase was not 
the main mechanism of resistance in these strains. All carbapenem-resistant P. aeruginosa 
were isolated from patients hospitalized in the ICU. Besides the high mortality rate, many 
patients remained hospitalized for several days, resulting in a high cost of hospitalization 
for the public health system. Therefore, the evolution of this resistance and its dissemination 
should be actively monitored among critically ill patients to improve their health conditions. 
KEYWORDS: Healthcare-associated infections. Antimicrobial resistance. Public health. 
Carbapenemase. 
INTRODUCTION
Pseudomonas aeruginosa is a common cause of serious healthcare-associated 
problems, usually causing urinary, respiratory, and bloodstream infections1. These 
infections can be fatal for critically ill and immunocompromised patients and are 
further exacerbated by antimicrobial resistance2. There is some evidence suggesting 
that patients who are infected by carbapenem-resistant pathogens have an increased 
likelihood of morbidity and mortality compared to those infected by susceptible 
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pathogens1,3,4. This is probably due to the administration 
of antibiotics with suboptimal or no effect against these 
organisms5. The resistance to carbapenem in Gram-
negative bacteria has become a global problem, which has 
driven the World Health Organization (WHO) to include 
carbapenem-resistant P. aeruginosa in the list of pathogens 
of high priority for the research and development of new 
antibiotics. According to the Centers for Disease Control 
and Prevention (CDC), an estimated 51,000 healthcare-
associated P. aeruginosa infections in US hospitals occur 
annually. More than 6,000 (13%) of these are multidrug-
resistant, with about 440 deaths per year6. 
In Brazil, the rate of multidrug-resistant P. aeruginosa 
in adult and neonatal ICUs increased from 35.6% to 39.1% 
and 18.2% to 29.3%, respectively7. The impact of the 
resistance of P. aeruginosa on health systems is a major 
concern and it has spread across hospitals mainly due to the 
frequent use of carbapenems, which has been considered the 
only effective antibiotic against P. aeruginosa infections8. 
Recognizing the risk of resistance to carbapenem especially 
in the most vulnerable patients and/or the early detection 
of specific carbapenem-resistance mechanisms are critical 
to reducing the risk of mortality, length of hospitalization, 
and associated costs3,9. To achieve this, identification 
and ongoing surveillance of carbapenem-resistant 
Gram-negative bacteria are needed. Here, we described 
the epidemiological and molecular characteristics of 
carbapenem-resistant P. aeruginosa strains isolated from 
patients hospitalized in ICUs.
MATERIALS AND METHODS
Study site and patients
Data were collected from patients hospitalized in 
a public tertiary care hospital in the municipality of 
Dourados, Mato Grosso do Sul State, Midwest Brazil, 
between November 2015 and August 2016. The hospital 
has 237 beds, distributed across the infirmaries and the 
ICUs (adult, pediatric, and neonatal). The hospital serves 
as a tertiary referral center for 32 cities, with an average 
of 9,800 annual admissions. The majority of the patients 
lived in Dourados, while the remaining lived in the 
surrounding cities.
Bacterial identification and susceptibility testing 
The identification of the bacterial species and the 
screening for antimicrobial resistance were performed by 
the Phoenix® Automated System (BD Diagnostic Systems, 
Sparks, MD, USA) according to the manufacturer’s 
instructions. After isolation, the susceptibility profile was 
confirmed, and the minimum inhibitory concentrations 
(MICs) of the antimicrobials were determined by broth 
microdilution following the recommendations of the 
Clinical and Laboratory Standards Institute guidelines 
(CLSI)10. 
PCR for resistance genes
Carbapenemase encoding genes were investigated by the 
polymerase chain reaction (PCR) and DNA sequencing11, 








































). The PCR products were 
purified with the QIAquick PCR purification kit (Qiagen, 
Hilden, Germany) and both strands were sequenced using 
the Applied Biosystems 3500 genetic analyzer equipment 
(Applied Biosystems, Thermo Fisher Scientific, Waltham, 
MA, USA). The nucleotide sequences and the deduced 
amino acid sequences were analyzed using the Lasergene 
software package (DNAStar, Madison, WI, USA) and 
compared with the sequences available on the Internet using 
the BLAST tool.
Porin expression and oprD mutations 
Mutations in OprD and its promoter region were 
identified by conventional PCR, and the amplicon size was 
analyzed by a 1.5% agarose gel electrophoresis12. The outer 
membrane proteins (OMPs) were isolated and visualized by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) using membrane extracts from bacteria grown 
in nutrient broth overnight, following which, the gels were 
stained with Coomassie blue. Pseudomonas aeruginosa 
ATCC 27853 was used as a reference strain.
Clinical data
The following data of all the patients participating in 
this study were recorded: demographics; location before 
admission; hospital course (duration); comorbidities, 
treatment regimens, source of infection, and outcome 
(recovery/death) (Table 1). Strict CDC definitions were used 
to determine whether an isolated organism was associated 
with colonization or infection. The presence of a clinical 
infection was determined by the medical diagnosis, and 
the decision to initiate antimicrobial therapy, as well as 
the isolation of a carbapenem-resistant P. aeruginosa 
strains, according to the following clinical criteria (sepsis, 
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Table 1 - Clinical characteristics of 28 patients infected/colonized with carbapenem-resistant Pseudomonas aeruginosa strains. 
Patient Gender Age (years) Clinical specimen
Lenght of 
stay (days)
Comorbidities HAI Outcome Treatment
1 M 47 Tracheal aspirates ND ND C ND ND
2 M 80 Tracheal aspirates 30 SAH, SEP, CARD I Death
MTZ/1,500 mg/5 d  
PIP+TAZ/13.5 g/ 5 d 
MEM/3,000 mg/ 6d/ 2,000 mg/ 18 d 
VANCO/2,000 mg/ 6d/1 000 mg/ 7 d 
PMB/50 mg/ 17 d 
TGC/ 200 mg/11 d
3 M 37 Urine culture 38 DM I Death
CRO/2,000 mg/4 d 
LVX/750 mg/ 2 d 
PIP-TAZ/4 g+ 0.5 g/ 3 d 
PMB/ 50 mg/ 20 d 
TEICO/ 800 mg/ 3 d 
TGC/100 mg/ 20 d 
MEM 3 g/26 d/3 g/ 5 d




MTZ/500 mg/ 13 d 
MEM/ 500 mg/ 17 d 
TEICO/ 400 mg/3 d/ 200 mg/14 d




AMP-SAM/1 g+ 0.5 g/ 4 d 
CLI/ 1,200mg/5d 
MEM/3 g/ 26d 
VAN/ 2 g/36 d 
PMB/ 50 mg/ 2 2d 
TGC/100 mg/ 1 d/50 mg/ 2 d
6 F 45 Tracheal aspirates ND ND C ND ND 
7 F 54 Tracheal aspirates 42
DM, SAH, CARD, 
SEP
C Death
MEM/3 g/ 26 d 
VANCO /2 g/ 8 d 
PMB/ 50 mg/ 26 d 
AMP-TAZ/1 g +0.5 g/ 1d 
LZD/ 1,200 mg/ 3 d 
TEICO/ 800 mg/ 5 d 
IMP+CIS/ 2 g/ 4 d 
TGC/ 100 mg/ 15 d





IMP+ CIS/2 g/ 4 d 
FEP/2 g/ 7 d 
MEM/6 g/5 d 
VANCO/ 3 g/ 1 d/2 g/1 d
9 M 84 Catheter 48 HEMAT, HYPER C Death
PIP+TAZ/ 4+0.5 g/ 5 d  
VAN/500 mg/ 12 d 
MEM/1,000 mg/ 7 d 
TGC/ 100 mg/d/ 50 mg /5 d 
TEICO/ 400 mg/ 3 d
10 F 24 Secretion culture 44 RESP, SEP C
Death 
MEM/ 3 g/ 14 d/3 g/19 d 
TEICO/ 800 mg/ 1 d/800 mg/8 d 
VANCO/500 mg/ 3 d 
TGC/100 mg/ 29 d 
PMB/ 50 mg / 17 d 
IMP+CIS/2 g/ 6 d
11 F 26 Urine culture ND NEURO, SEP I Recovery
MEM/ 1 g/28 d/3 g/ 14 d/3 g/19 d 
PMB/50 mg/ 20 d 
VAN/ 500 mg/17 d 
GEN/ 240 mg/9 d/80 mg/4 d 
TEICO/ 200 mg/ 24 d
12 F 34 Urine culture ND ND C ND ND 




PIP-TAZ/ 4g-0.5 g/ 10 d 
AMK/ 500 mg/ 3 d
14 M 35 Tracheal aspirates 15 RESP I Recovery AMOX+CLAV/ 500 mg-100 mg/ 15 d
15 F 65 Urine culture 30 ND I Recovery
IMP+CIS/500 mg-500 mg/24 d 
TEICO/400 mg/ 7 d 
PMB/ 50 mg/ 20 d
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Patient Gender Age (years) Clinical specimen
Lenght of 
stay (days)
Comorbidities HAI Outcome Treatment
16 F 70 Tracheal aspirates 38
DM, DEC, SAH, 
SEP
C Death
MEM/ 3,000 mg/1 d/2,000 mg/6 
d/2,000mg/ 14 d 
IMP+CIS/ 500 mg-500mg/ 17 d 
VAN/2,000 mg/14 d 
GEN/80 mg/ 14 d 
PMB/ 50 mg/ 14 d






CRO 200 mg/ 5 d 
PIP+TAZ/ 4g-0.5g/3 d 
MEM 3 g/2 d/1.5 g/5 d 
VAN 2 g/16 d 
IMI+CIS/500 mg-500 mg/15 d
18 M 81 Tracheal aspirates 30 ND C Recovery
AMP-SAM/1g+0.5 g/7 d 
LZD/1,200 mg/2 d 
PMB/ 50 mg/ 7 d
19 M 76 Urine culture 23
SAH, CARD, 
REN, 
C Death ND 




CLI/ 150 mg/mL/ 7 d 
TZP/4 g-0.5 g/ 5 d 
TEICO/800 mg/ 2 d/ 400 mg/6 d 
PMB/ 50 mg/22 d 
SXT+ TMP/40 mL/ 3 d 
GEN/80 mg/2 d 
MEM/ 2 g/14 d/3 g/ 12 d 
AMP-SAM/ 1 g-0.5 g/ 13 d
21 M 76 Tracheal aspirates 25 PNA I Death
PIP-TAZ/ 4 g-0.5 g/ 4 d 
VAN/500 mg/1 d 
MEM/ 1 g/ 11 d 
PMB/50 mg/ 5 d
22 F 28 Urine culture 30 NEURO, SEP C Recovery
GEN/80 mg/ 7 d 
PMB/50 mg/ 14 d 
TEICO/400 mg/ 7 d 
TGC/80 mg/7 d 
MEM/3 g/ 7 d/6 g/ 12 d 
CIP/1,200 mg/1 d/800 mg/11 d 
SXT+ TMP/80 mL/ 7 d
23 M 51 Secretion culture 13 DM, SAH, RESP C Recovery
MEM/ 3 g/2 d 
LZD/ 1,200 mg/1d 
PMB/50 mg/ 1 d
24 F 21 Urine culture 30 RESP, SEP I Recovery
MEM/ 3 g/ 4 d 
PMB/50 mg//16 d 
GEN/80 mg/ 16 d
25 M 81 Secretion culture 28 RESP, NEURO C Recovery
AMP-SAM/1 g +0.5 g/11 d 
PMB/50 mg/ 15 d




VAN 1 g/ 21 d 
MEM 1 g/ 21 d
27 F 48 Secretion culture 39 SAH, SEP C Recovery
CRO/2,000 mg/ 8 d 
MTZ/2,000 mg/ 7 d 
IMP+CIS/ 500 mg/12 d 
PMB/50 mg/14 d 
TEICO/800 mg/3 d/400 mg/ 9 d 
GEN/80 mg/ 5 d 
MEM/3,000 mg/1 d/2000 mg/11 d
28 F 1 Secretion culture 30 RESP, PNA C Recovery
CFE/3 mL/4 d/ 4 mL/8 d 
MEM/3.6 mL /10 d 
AMK/ 1 mL/ 1 d/0.7 mL/ 9 d
Treatments: Amikacin (AMK), Amoxicillin(AMOX), Clavulanatepotassium (CLAV), Ciprofloxacin (CIP), Gentamycin (GEN), imipenen (IMP), levofloxacin (LEV), 
meropenem (MEM), Piperaciclin (PIP), Polimyxin B (PMB), Tigeciclin (TGC), Ampicilin + sulbactam (AMP-SAM), cefalexin ( CFE), Teicoplamin (TEICO), 
Metronidazole (MTZ), sulfametoxazole+ trimetropim (SXT-TMP), Vancomycin (VAN), Cilastatin (CIS), Linezolid (LZD), ceftriaxone (CRO), Clindamicin (CLI), 
Levofloxacin (LVX), Tazobactam (TAZ); Comorbidities: Alcoholism (ALCOH), Cancer (CANC), Cardiovascular disease (CARD), Chronic Obstructive Pulmonary 
disease (COPD), Decubitus ulcers (DEC), Diabetes Mellitus (DM), Hyperthroidism (HYPER), Neurological disease (NEURO), Pneumonia (PNA), Renal Failure 
(REN), Respiratory Failure (RESP), Systemic Arterial Hypertension (SAH), Sepsis (SEP), Tabagism (TAB); Healthcare-associated Infections (HAI): Infeccion 
(I), Colonization (C); ND = not detected.
Table 1 - Clinical characteristics of 28 patients infected/colonized with carbapenem-resistant Pseudomonas aeruginosa strains. (cont)
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fever, changes in the frequency or color of secretions, or 
new radiological findings)13. Colonizers were defined as 
bacteria permanently or temporarily present on the skin 
or the mucous membranes of the patients, irrespective of 
the signs or symptoms of infection. The endemic level of 
colonization and infection by carbapenem-resistant strains 
per 1,000 patients-days was calculated using a previously 
described method14. The costs of hospitalization of the 
patients in ICUs were estimated using data from the Unified 
Health System (SUS) of Brazil. We consulted the average 
daily cost in the ICU by specialty, in the municipality of 
Dourados, Mato Grosso do Sul State, in December-2020, 
through the official database of Analytical Audit in SUS 
Hospitalizations (DATASUS). 
Ethical standards
This study was conducted with the approval of the 
Research Ethics Committee from Universidade Federal da 
Grande Dourados (Nº 877.292/2014).
RESULTS
Antimicrobial susceptibility testing
Twenty-eight carbapenem-resistant P. aeruginosa strains 
were isolated from patients hospitalized in an ICU. All the 
strains exhibited resistance to IMP and MEM with MICs 
ranging from 32 to ≥ 128 µg/mL and from 8 to ≥128 µg/mL, 
respectively. This resistance was observed in 75% (21/28) 
of the isolates for ATM (MIC range: ≥ 8 to 16 µg/mL), 
68% (19/28) for GEN (MIC range: ≥ 2 to 8 µg/mL), 60% 
(17/28) for CAZ (MIC range: ≥ 2 to 16 µg/mL), 71% (20/28) 
for FEP (MIC range ≥ 2 to 16 µg/mL), 71% (20/28) for PIP 
(MIC range ≤ 4 to ≥ 64 µg/mL), 71% (20/28) for CIP (MIC 
range ≤ 0.5 to ≥ 2 µg/mL), 53% (15/28) for AMK (MIC 
range ≤ 8 to ≥ 32 µg/mL), 3.5% (01/28) for CST (MIC 
range ≤ 1to ≥ 4 µg/mL), and 68% (19/28) for LEV (MIC 
range ≤ 2 to ≥ 4 µg/mL). Individual results are described in 




 gene was detected in 11% (3/28) of the 
carbapenem-resistant P. aeruginosa strains, bla
KPC-2
 in 
11% (3/28), and bla
SHV 
in 7% (2/28) of the resistant 























genes were not amplified. The PCR analysis of the oprD 
porin gene failed to amplify all the isolates (100%) (S1). 
According to the SDS–PAGE results, OprD was not 
identified, suggesting that OprD was either absent or was 
produced at very low levels by all isolates (Table 1).
Clinical data 
The carbapenem-resistant P. aeruginosa strains were 
isolated from 28 patients hospitalized in ICUs, whose 
median duration of stay was 34.4 days. Previously, 75% 
(21/28) of the patients were hospitalized in another hospital. 
Out of the 28 patients, 43% (n = 12/28) were female, their 
ages ranging from 1 to 84 years (median 48.9). Regarding 
the history of comorbidities, 43% (12/28) of the patients 
had sepsis, 31% (9/28) had respiratory failure, 31% (9/28) 
had systemic arterial hypertension, 28.5% (8/28) had 
neurological diseases, 25% (7/28) had cardiovascular 
diseases, 14% (4/28) had pneumonia, 14% (4/28) had 
diabetes mellitus, 7% (2/28) had a smoking history, and 
7% (2/28) were alcoholic (Table 1). Carbapenem-resistant 
P.  aeruginosa strains were recovered from tracheal 
secretions in 43% (12/28) of the patients, from urine in 
28.5% (08/28) of the patients, from secretions culture in 21% 
(06/28) of the patients, from blood cultures in 3.5% (01/28) 
of the patients, and from intravenous catheters in 3.5% 
(01/28) of the patients. Among the carbapenem-resistant 
strains, 28.5% (8/28) were considered true pathogens (I) 
and 71.5% (20/28) were colonizers (C) (Table  1). The 
three most common treatment regimens used in the patients 
were: carbapenems (meropenem, imipenem) in 89% 
(25/28), polypeptides (polymyxin B) in 82% (23/28), and 
glycopeptides (teicoplanin, vancomycin) in 53.5% (15/28). 
The mortality rate of patients infected or colonized with 
carbapenem-resistant P. aeruginosa was 39% (11/28).
Regarding the endemicity of carbapenem-resistant 
P. aeruginosa strains, the rate of occurrence of infection 
and/or colonization per 1,000 patient-days in June 
2016 exceeded the average incidence of colonization/
infection, as per the established alert limit (Figure 1). The 
acquisition rate of infection and/or colonization was 0.01 
per 1,000 patient-days in May 2016, increasing to 0.03 
per 1,000 patient-days in June 2016. Although initially 
it did not exceed the control limit, subsequent cases led 
the acquisition rate of carbapenem-resistant strains to rise 
above the mean prevalence, causing it to reach the alert 
limit at different times of the study period. Patients infected 
or colonized with carbapenem-resistant strains remained 
hospitalized for a minimum of 13 days. Each patient 
infected or colonized with carbapenem-resistant strains 
spent a median of US$ 3.174,87 in the treatment (Brazilian 
reals were converted to U.S. dollars using the quotation of 
December 21, 2020 when R$ 5.22 = US$ 1.00, resulting 
in US$ 91.70 per day of hospitalization.
Souza et al.
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DISCUSSION
The prevalence of antimicrobial resistance is increasing, 
probably due to the widespread use of carbapenems in the 
hospital environment. This can selectively increase the 
pressure on the hospital microbiota, in turn, increasing the 
emergence and spread of resistant bacteria; thus, affecting 
the morbidity and mortality of the patients15. The ICUs are 
the major sources of dissemination of multidrug-resistant 
organisms, where the selection pressure is the highest for 
the emergence of resistance. The nosocomial infection rate 
in ICUs is 2–5 times higher than that in the general (non-
ICU) hospital population16. Interestingly, in our study, all 
carbapenem-resistant P. aeruginosa strains were isolated 
from patients hospitalized in the ICU, indicating that in 
this hospital, the frequency of these strains is restricted to 
the ICU.
Out of the 28 carbapenem-resistant P. aeruginosa 
strains evaluated, only three KPC-producing P. aeruginosa 
strains were identified. The production of carbapenemase 
has emerged in Brazil as the main mechanism of resistance 
to carbapenem among clinical isolates of P. aeruginosa17. 
However, the low rates of KPC-producing P. aeruginosa 
observed suggest that other mechanisms could be involved 
in the evolution of resistance. In our study, OprD porin was 
absent or was produced at very low levels in carbapenem-
resistant P. aeruginosa, indicating that the loss of OprD has 
contributed to carbapenem resistance18. Sequence changes 
including amino acid deletions or substitutions, probably 
led to an increase in the minimum inhibitory concentration 
of carbapenems19. The emergence of resistance to 
P. aeruginosa to carbapenems associated with the loss of 
porin by an insertion sequence element has been associated 
with an increase in the MIC of imipenem and meropenem 
from 0.5 and 2 µg/mL, respectively, to up to 16 µg/mL20. 
Several studies have reported that mutations, insertions, 
and/or deletions are responsible for inactivating the oprD 
gene, therefore conferring resistance to imipenem and 
meropenem in clinical isolates of P. aeruginosa recovered 
worldwide21-27. Thus, the deficiency of the outer membrane 
protein OprD appears to be the mechanism involved 
in the resistance of P. aeruginosa strains evaluated in 
our study. Several mechanisms are involved in the drug 
resistance of P. aeruginosa28. In general, these mechanisms 
coexist simultaneously, conferring a combined resistance 
to many antibiotics, narrowing the treatment options. 
The intrinsic resistance involves the overexpression of 
efflux pumps and their low permeability to the outer 
membrane28, whereas the acquired resistance involves 
the acquisition of resistance genes or mutations in genes 
encoding porins, efflux pumps, penicillin-binding proteins, 
and chromosomal β-lactamase, all contributing to the 
resistance to β-lactams, carbapenems, aminoglycosides, 
and fluoroquinolones29.
The carbapenem-resistant P. aeruginosa strains were 
isolated from patients hospitalized in ICUs for long periods 
(mean 34.4 days). They had several comorbidities and poor 
outcomes (39% mortality rate). The emergence of resistance 
during treatment is associated with increased morbidity, 
mortality, and health costs30. Pseudomonas aeruginosa is 
one of the main pathogens in ICUs31 responsible for high 
mortality rates, ranging from 24.8% in patients infected 
with sensitive P. aeruginosa to 44.6% in patients infected 
with multidrug-resistant P. aeruginosa32. The acquisition 
of carbapenem-resistance in P. aeruginosa strains plays an 
important role in the high mortality rates. However, they 
Figure 1 - Endemic level of colonization/infection due to carbapenem-resistant P. aeruginosa strains per 1,000 patient-days from 
November 2015 to August 2016. Upper control limit (3σ+X); upper alert limit (2σ+X); X: centerline (mean rate of P. aeruginosa strains 
per 1,000 patient-days).
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are not the only factor responsible for the poor outcomes 
observed in the studied patients, considering that they 
displayed several other unfavorable clinical conditions33-37. 
Besides having negatively impacted the clinical 
outcomes, carbapenem resistance has also created an 
undue economic burden with a high cost of hospitalization 
(median cost of US$ 3.174,87, for 34.61 days) as we 
have demonstrated here. Previous studies showed that 
carbapenem resistance was a significant predictor of 
in-hospital mortality38 and resulted in an increase in 
hospital-related costs37. The resistance of P. aeruginosa to 
antimicrobials is a global problem, especially in countries 
with limited resources, due to the need for new treatment 
options and improvement of basic practices for the 
prevention and surveillance of infections39. In hospitals, 
an active surveillance for the early detection of colonized 
patients is necessary to prevent institutional outbreaks and to 
limit dissemination; the early intervention to prevent death 
through the administration of antimicrobials is effective in 
controlling the threat40. 
There are, however, some limitations in our study. 
Firstly, it was performed in only one hospital. Thus, the 
prevalence and molecular characteristics of carbapenem-
resistant P. aeruginosa strains may not be generalizable 
across the country. In addition, we had several difficulties 
in determining the clinical characteristics of some patients 
from whom the carbapenem-resistant P. aeruginosa strains 
were isolated, so that they were excluded from the study. 
Excluding the limitations, our study added important data 
to the literature by showing that patients hospitalized 
in ICUs are primarily affected by carbapenem-resistant 
P. aeruginosa strains. Additionally, the production of 
carbapenemases may not be the main mechanism of 
resistance in P. aeruginosa strains circulating in the hospital. 
Our results showed that alterations in OprD may 
be responsible for the resistance to carbapenem among 
P.  aeruginosa isolated from patients hospitalized in 
Dourados, Brazil. Identifying the factors that can influence 
the mobilization and insertion of elements that disrupt 
the oprD gene can contribute significantly to our current 
knowledge of mechanisms involved in the emergence of 
antibiotic resistance and the evolution of P. aeruginosa. 
Additionally, stricter measures to contain the spread of 
multi-resistant microorganisms can contribute to the 
reduction of mortality of patients hospitalized in ICUs, as 
well as to reduce the costs of hospitalization.
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